Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Short Interest Down 6.0% in January

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) saw a significant drop in short interest in the month of January. As of January 31st, there was short interest totalling 139,100 shares, a drop of 6.0% from the January 15th total of 148,000 shares. Based on an average trading volume of 13,200 shares, the days-to-cover ratio is presently 10.5 days. Currently, 0.5% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. RODMAN&RENSHAW raised shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, November 14th. Rodman & Renshaw initiated coverage on shares of Eupraxia Pharmaceuticals in a report on Thursday, November 14th. They issued a “buy” rating and a $9.00 target price on the stock.

Eupraxia Pharmaceuticals Stock Up 1.2 %

NASDAQ:EPRX opened at $3.28 on Tuesday. The stock has a market cap of $116.83 million and a P/E ratio of -4.56. The firm’s fifty day simple moving average is $3.12 and its 200 day simple moving average is $2.88. Eupraxia Pharmaceuticals has a twelve month low of $2.20 and a twelve month high of $5.58.

Institutional Trading of Eupraxia Pharmaceuticals

A number of hedge funds have recently modified their holdings of the business. Millennium Management LLC bought a new stake in shares of Eupraxia Pharmaceuticals during the 4th quarter valued at $31,000. Raymond James Financial Inc. purchased a new position in Eupraxia Pharmaceuticals in the 4th quarter worth about $37,000. Finally, Bank of Montreal Can raised its position in Eupraxia Pharmaceuticals by 15.2% in the 4th quarter. Bank of Montreal Can now owns 56,750 shares of the company’s stock worth $178,000 after buying an additional 7,500 shares during the last quarter.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.